Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 3.7% – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) rose 3.7% during mid-day trading on Tuesday . The stock traded as high as $7.20 and last traded at $7.02. Approximately 4,972,649 shares were traded during trading, a decline of 28% from the average daily volume of 6,902,442 shares. The stock had previously closed at $6.77.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Stock Down 0.1 %

The stock’s 50-day simple moving average is $6.82 and its 200-day simple moving average is $7.09. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.94 billion, a P/E ratio of -4.42 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the previous year, the business posted ($0.43) earnings per share. The business’s revenue was up 147.6% compared to the same quarter last year. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other news, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $6.31, for a total transaction of $37,860.00. Following the completion of the transaction, the chief operating officer now owns 521,138 shares of the company’s stock, valued at $3,288,380.78. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 70,341 shares of company stock worth $488,290. 15.75% of the stock is owned by company insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC bought a new position in Recursion Pharmaceuticals in the 3rd quarter worth about $25,000. Farther Finance Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares in the last quarter. KBC Group NV boosted its position in shares of Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after acquiring an additional 3,377 shares during the period. Amalgamated Bank grew its stake in Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares in the last quarter. Finally, San Luis Wealth Advisors LLC bought a new stake in Recursion Pharmaceuticals during the 3rd quarter worth approximately $69,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.